Purpose: Early research suggests prolonged ischemic time in older donor lungs is associated with decreased survival following lung transplantation. The purpose of this study was to determine whether this association holds in the post-lung allocation score era.
| Variables
Patient and donor baseline characteristics, transplant characteristics, operative variables, and outcomes were compiled. Diagnoses were categorized into four groups including "obstructive lung disease," "restrictive lung disease," "cystic fibrosis/immunodeficiency," and "other." Functional status as defined by Karnofsky score was grouped into "performing activities of daily living [ADL] with no assistance" (Karnofsky score 70-100), "performing ADLs with assistance" (Karnofsky score 50-60), or "disabled/hospitalized" (Karnofsky score . Linearity was evaluated for all continuous variables by plotting the variable against the log odds of 1-year mortality. Variables that were not linear were categorized based on a subjective assessment of the plot of the variable and the log odds of 1-year mortality. Variables were not transformed to aid in clinical utility. Survival was defined as the time from transplant to either death or retransplantation. Living recipients were censored at the time of last follow-up.
| Statistical analysis
Patients were initially grouped by donor age and compared for baseline and transplant-related characteristics. Continuous variables were compared using the Kruskal-Wallis test while categorical variables were compared using either Fisher's exact test or the chi-square test as appropriate. Patients were also grouped by ischemic time and compared in a similar manner.
Kaplan-Meier analysis and Cox proportional hazards regression modeling were then utilized to determine the association of transplant-free survival with both ischemic time and donor age.
Variables included in the Cox model were based on clinical relevance and included recipient and donor characteristics as well as center volume over the study period. Recipient characteristics included in the model were age, sex, diagnosis group, hypertension, diabetes, body mass index (BMI), pre-transplant creatinine, functional status, bilateral vs single lung transplantation, and ischemic time. Donor characteristics included age and a diagnosis of diabetes. An interaction term was initially included between donor age and ischemic time, but a decision was made a priori to remove the term from the final model if found to be non-significant. A subgroup analysis was also performed among single (SOLT) and bilateral (BOLT) orthotopic lung transplant recipients to determine whether the association of donor age and ischemic time and transplant-free survival varied among these cohorts.
The proportional hazards assumption was tested for all Cox models. A P-value of .05 was used to define statistical significance. All statistical analyses were performed using R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria).
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on an assessment of this association. Donor age was divided into ages 0-20 (n=2,439, 21.7%), 21-50 (n=6,725, 59.8%), 50-59 (n=1,625, 14.5%), and 60 or older (n=456, 4.1%). Recipients who received lungs from older donors tended to be older, were more likely to be female, were more likely to have obstructive lung disease, and had worse functional status (Table 1) . Furthermore, patients who received lungs from older donors also tended to spend less time on the waiting list. Lastly, patients who received lungs from older donors tended to receive their transplant at higher volume centers.
Ischemic time was also divided into four groups: <4 hours (n=2,898, 24.8%), 4-6 hours (n=5,439, 48.4%), 6-8 hours (n=2,372, 21.1%), and >8 hours (n=536, 4.8%). Patients who received lungs subjected to longer ischemic times tended to be younger, were less likely to be female, were less likely to have obstructive lung disease and were more likely to have cystic fibrosis, and had better preoperative functional status (Table 2) . Patients with longer ischemic times were also more likely to undergo BOLT vs SOLT and were also more likely to be transplanted at higher volume centers.
Upon unadjusted analysis, a donor age of 60 or greater was found to be associated with a significantly worse long-term survival as compared to younger donor ages, with a 5-year survival of only 42.4% (95% confidence interval [CI]: 36.5%, 49.3%, Figure 2 ). An ischemic time of >8 hours was similarly found to be associated with worse survival within 90 days of transplant (compared to <4 hours; hazard ratio Upon adjustment with Cox modeling, the interaction term between donor age and ischemic time was consistently found to be non-significant, and was therefore removed from the model. In the overall cohort, after adjustment, only donor age >50 remained significantly associated with reduced long-term survival (donor age 50-60:
adjusted HR: 1.11, 95% CI: 1.01, 1.24, donor age >60: adjusted HR:
1.42, 95% CI: 1.21, 1.65, Figure 4 ). Ischemic time was not found to be significantly associated with long-term survival. Among patients undergoing a SOLT, donor age >60 remained significantly associated with reduced long-term survival (adjusted HR: 1.29, 95% CI: 1.02, 1.64).
Among patients undergoing a BOLT, donor age between 50 and 60 was associated with significantly reduced long-term survival (adjusted HR: 1.15, 95% CI: 1.00, 1.31) as was a donor age >60 (adjusted HR:
1.52, 95% CI: 1.24, 1.88).
| DISCUSSION
The last decade has seen substantial modifications in lung transplantation, much of it secondary to the implementation of the LAS in 2005. 12 Furthermore, post-transplant survival has been steadily improving over time, although this is less likely to be associated with the LAS and more likely secondary to improving post-transplant care as well as more modern transplantation techniques. 2, 14 In this study, we have demonstrated that in the current era, there does not appear to be an interaction between donor age and ischemic time as seen previously by Meyer and colleagues. 9, 10 We did demonstrate, however, that donor age continues to be a significant factor in long-term survival, especially among donors >50 years of age.
We are not the first to demonstrate an association between advanced donor age and reduced survival among lung transplant recipients. Pilcher and colleagues demonstrated that donor age as a continuous variable was associated with early graft dysfunction following transplantation as defined by P AO2 /F IO2 ratios (arterial blood gas partial pressure of oxygen/fraction of inspired oxygen), although not all studies agreed with these findings. 8, 15 Other studies have demonstrated that the association between donor age and survival may be dependent on other factors such as recipient pulmonary hypertension status or prolonged cardiopulmonary bypass times. 16 More recent analyses by Hayes and colleagues demonstrated that this association may be dependent on recipient age as well, as older donor lungs only appeared to have a significant negative association with long-term survival among older recipients. 17 Lastly Bittle and colleagues demonstrated that the use of donor lungs >65 years of age was associated with significantly reduced survival. 18 Although Meyer and colleagues did not demonstrate an "independent" association between ischemic time and survival, a study performed by Thabut and colleagues between 1987 and 1998 did F I G U R E 2 Transplant-free survival by donor age demonstrate an association between ischemic time and both early graft function as well as long-term survival. 9, 10, 19 In our examination of the more current experience, we were not able to demonstrate either an association between ischemic time and overall survival, nor an interaction between ischemic time and donor age and overall survival. There are likely several reasons for the different conclusions, most importantly due to improvements in organ preservation and other transplantation techniques. An important concern with our findings was our inability to demonstrate an association between ischemic time and overall survival, a potential type II statistical error. This is unlikely, as a key change in the modern era has been the use of longer ischemic times in general, which contributed to the larger number of patients in the prolonged ischemia group in our study (536 as compared to 384 in the Novick study and 245 in the Meyer study). 9,10 Therefore, it is very unlikely that our findings are solely due to insufficient power. As a final note with regards to early and late survival in recipients of allografts with long ischemic times, it appears that an early survival disadvantage is tempered by a modest survival advantage late (after 90 days). This finding may be related to an increased fraction of BOLT recipients receiving grafts with longer ischemic times, in which increased early morbidity and mortality related to the more invasive procedure is tempered by a late survival advantage. These data should be considered in the subsequent analysis in which the role of ischemic time is examined separately within BOLT and SOLT recipients. We also demonstrated that higher volume centers tended to be more likely to transplant more "marginal" donors, both with regards to using lungs from older donors, as well as using lungs which required longer periods of ischemia. Transplantation at a higher volume center has previously been associated with improved survival, however, to attain this volume, these centers are likely more capable of accepting organs from extended criteria donors or organs from greater distances away. 20 Nonetheless, we included center volume in our model, and therefore, it is unlikely that the optimal survival associated with a high There are also limitations to this study which limit the generalizability of our findings. First, although there is substantial variation in both donor age and ischemic time in the UNOS database, there are few transplants performed at the high-end of the spectrum for both, thus limiting the power of this study. It is obvious that there is a time point at which lungs not being perfused will not perform as well following transplant, however as centers currently limit ischemic time as much as possible, we did not have the power to determine this point. Second, as a retrospective study of a national registry, there is always the potential for unmeasured confounding which could not be accounted for in the adjustment, including organ preservation methods and variation in post-transplant practices. Third, we decided to categorize the primary predictors (donor age and ischemic time) instead of transforming the variables as continuous variables, which may also have reduced the power of the study. However, categorized variables are much more useful clinically, which is the reason we pursued this approach.
In conclusion, we have demonstrated that in contrast to previous studies, prolonged ischemic time is not significantly associated with overall survival in patients undergoing either a SOLT or BOLT regardless of the donor's age. Although we cannot determine from this analysis the etiology for this change from previous studies, we hypothesize that it may also be secondary to changes in practice and organ allocation following the implementation of the LAS, or related to improved preservation techniques and post-transplant care. In addition, we have continued to demonstrate that advanced donor age is associated with decreased long-term survival, although the donor age at which survival begins to decline varies by the type of transplant. In appropriately selected recipients and in centers with high volume, we suggest that the lack of an association between ischemic time and survival should encourage a cautiously increased geographic allocation of pulmonary allografts.
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